Traws Pharma (TRAW) director granted 15,609 options at $1.89

Traws Pharma (TRAW) reported an insider equity award.

Accepted by SEC EDGAR 10/14/2025 - 07:03 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Traws Pharma (TRAW) reported an insider equity award. On 10/01/2025, a company director received a stock option grant covering 15,609 shares of common stock at an exercise price of $1.89 per share.

The options expire on 10/01/2035 and were reported with a derivative security price of $0. The award vests over three years from the grant date: 33% on the first anniversary, 33% on the second, and 34% on the third. The filing lists direct (D) ownership following the transaction.

Insider Trade Summary

Grant/Award: 15,609 shares

Grant/Award 1 txn

Insider Leaman John Harold

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to purchase)	15,609	$0.00	$0.00

Holdings After Transaction: Stock Option (right to purchase) — 15,609 contracts (Direct)

Holdings Before and After: Stock Option (right to purchase), 0 to 15,609 contracts (Direct)

Footnotes (1)

1. F1. These options vest over three years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did TRAW disclose in this Form 4?

A director received a stock option grant for 15,609 shares at an exercise price of $1.89 on 10/01/2025.

What is the vesting schedule for the TRAW options?

The options vest over three years: 33% after one year, 33% after two years, and 34% after three years from the grant date.

When do the TRAW options expire?

The options expire on 10/01/2035.

What is the ownership form after the transaction?

The filing lists Direct (D) ownership of the derivative securities.

What price was reported for the derivative security?

The filing reports a derivative security price of $0 and an exercise price of $1.89 per share.

Who is the issuer and ticker symbol?

The issuer is Traws Pharma, Inc. with ticker TRAW.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Leaman John Harold

(Last) (First) (Middle)

C/O TRAWS PHARMA, INC.

12 PENNS TRAIL

(Street)

NEWTON PA 18940

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to purchase)	$1.89	10/01/2025		A		15,609		(1)	10/01/2035	Common Stock	15,609	$0	15,609	D

Explanation of Responses:

1. These options vest over three years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary.

	/s/ John Leaman	10/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.